Report Detail

Pharma & Healthcare Eastern Equine Encephalitis - Pipeline Review, H2 2019

  • RnM3856001
  • |
  • 22 July, 2020
  • |
  • Global
  • |
  • 41 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Eastern Equine Encephalitis - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eastern Equine Encephalitis - Pipeline Review, H1 2020, provides an overview of the Eastern Equine Encephalitis (Infectious Disease) pipeline landscape.

Eastern equine encephalitis is a disease that is spread to humans by infected mosquitoes. Eastern equine encephalitis is caused by the Eastern equine encephalitis virus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eastern Equine Encephalitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Eastern Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eastern Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Eastern Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Eastern Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Eastern Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Eastern Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Eastern Equine Encephalitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Eastern Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Eastern Equine Encephalitis - Overview

              Eastern Equine Encephalitis - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Eastern Equine Encephalitis - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Eastern Equine Encephalitis - Companies Involved in Therapeutics Development

                                      Bavarian Nordic A/S

                                        Profectus BioSciences Inc

                                          Ridgeback Biotherapeutics LP

                                            Eastern Equine Encephalitis - Drug Profiles

                                              EIDD-2801 - Drug Profile

                                                Product Description

                                                  Mechanism Of Action

                                                    R&D Progress

                                                      encephalitis (trivalent,virus like particle) vaccine - Drug Profile

                                                        Product Description

                                                          Mechanism Of Action

                                                            R&D Progress

                                                              equine encephalitis (trivalent) vaccine - Drug Profile

                                                                Product Description

                                                                  Mechanism Of Action

                                                                    R&D Progress

                                                                      equine encephalitis vaccine - Drug Profile

                                                                        Product Description

                                                                          Mechanism Of Action

                                                                            R&D Progress

                                                                              Small Molecule for Eastern Equine Encephalitis and Venezuelan Equine Encephalitis - Drug Profile

                                                                                Product Description

                                                                                  Mechanism Of Action

                                                                                    R&D Progress

                                                                                      Small Molecule to Inhibit Myd88 for Infectious Diseases, Inflammation, Septic Shock and Toxic Shock - Drug Profile

                                                                                        Product Description

                                                                                          Mechanism Of Action

                                                                                            R&D Progress

                                                                                              TSI-GSD-104 - Drug Profile

                                                                                                Product Description

                                                                                                  Mechanism Of Action

                                                                                                    R&D Progress

                                                                                                      Eastern Equine Encephalitis - Dormant Projects

                                                                                                        Eastern Equine Encephalitis - Product Development Milestones

                                                                                                          Featured News & Press Releases

                                                                                                            Apr 18, 2019: UofL researcher developing drug to treat emerging encephalitis viruses

                                                                                                              Jan 24, 2019: Bavarian Nordic advances development of equine encephalitis virus vaccine

                                                                                                                Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses

                                                                                                                  Appendix

                                                                                                                    Methodology

                                                                                                                      Coverage

                                                                                                                        Secondary Research

                                                                                                                          Primary Research

                                                                                                                            Expert Panel Validation

                                                                                                                              Contact Us

                                                                                                                                Disclaimer

                                                                                                                                Summary:
                                                                                                                                Get latest Market Research Reports on Eastern Equine Encephalitis. Industry analysis & Market Report on Eastern Equine Encephalitis is a syndicated market report, published as Eastern Equine Encephalitis - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Eastern Equine Encephalitis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                Last updated on

                                                                                                                                REPORT YOU MIGHT BE INTERESTED

                                                                                                                                Purchase this Report

                                                                                                                                $2,000.00
                                                                                                                                $4,000.00
                                                                                                                                $6,000.00
                                                                                                                                1,606.00
                                                                                                                                3,212.00
                                                                                                                                4,818.00
                                                                                                                                1,870.00
                                                                                                                                3,740.00
                                                                                                                                5,610.00
                                                                                                                                310,260.00
                                                                                                                                620,520.00
                                                                                                                                930,780.00
                                                                                                                                166,700.00
                                                                                                                                333,400.00
                                                                                                                                500,100.00
                                                                                                                                Credit card Logo

                                                                                                                                Related Reports


                                                                                                                                Reason to Buy

                                                                                                                                Request for Sample of this report